Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726046 | 0.85 | ALOX5 (0.47) | ALOX5KDM4EPOLBATMLMNA | |
| SCHEMBL1612190 | 0.85 | TSHR (0.49) | TSHRALDH1A1HSD17B10ADRA1DADRA1A | |
| SCHEMBL18665582 | 0.83 | KDM4E (0.43) | KDM4ELMNAALDH1A1HSD17B10ADORA2A | |
| SCHEMBL1340046 | 0.81 | ALOX5 (0.40) | ALOX5KDM4ETSHRALDH1A1HSD17B10 | |
| SCHEMBL22717944 | 0.80 | ALDH1A1 (0.42) | ALOX5KDM4ELMNAALDH1A1ADORA2A | |
| SCHEMBL29574006 | 0.80 | ALDH1A1 (0.42) | ALOX5KDM4ELMNAALDH1A1ADORA2A | |
| SCHEMBL7299146 | 0.80 | PARP1 (0.57) | KDM4ETSHRTRPA1ALDH1A1HSD17B10 | |
| SCHEMBL24099704 | 0.80 | ABL1 (0.37) | KDM4EPOLBATMLMNAALDH1A1 | |
| SCHEMBL30874417 | 0.80 | ABL1 (0.37) | KDM4EPOLBATMLMNAALDH1A1 | |
| SCHEMBL24100076 | 0.80 | KDM4E (0.38) | ALOX5KDM4EPOLBATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-105001178-B | The synthetic method of Azasetron hydrochloride intermediate | 上海信谊万象药业股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-2509600-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION | AGIOS PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-06-15 | — | — | US | disclosed |
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| EP-2264031-B1 | A NOVEL BENZOXAZINE BENZIMIDAZOLE DERIVATIVE, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND A USE THEREOF | DAE WOONG PHARMA (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2008100463-A1 | 3,4-DIHYDR0-L,4-BENZ0XAZINE, 3, 4-DIHYDR0-1, 4-BENZOTHIAZINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2007-04-26 | — | — | US | disclosed |
| EP-1777225-A1 | FUSED BENZAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| WO-2007024949-A2 | ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166541-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, CD44 | ALOX5 1465/4885KDM4E 3489/4885POLB 356/4885 |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | TRPV1, TRPV2, TRPA1 | ALOX5 1945/4885KDM4E 3141/4885POLB 4638/4885 |
| US-20070093477-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | ALOX5 2807/4885KDM4E 3890/4885POLB 4481/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | ALOX5 3177/4885KDM4E 3259/4885POLB 2993/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | ALOX5 2372/4885KDM4E 3943/4885POLB 1911/4885 |
| US-20080039439-A1 | Alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | ALOX5 2807/4885KDM4E 3890/4885POLB 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.